156 related articles for article (PubMed ID: 38316287)
21. The Role of Urinary miRNAs in the Diagnosis, Management and Follow- Up of Prostatic Cancer.
Ziogou A; Giannakodimos A; Giannakodimos I
Microrna; 2023; 12(2):83-86. PubMed ID: 36999432
[TBL] [Abstract][Full Text] [Related]
22. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
23. Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients.
Moreira-Barbosa C; Barros-Silva D; Costa-Pinheiro P; Torres-Ferreira J; Constâncio V; Freitas R; Oliveira J; Antunes L; Henrique R; Jerónimo C
Clin Epigenetics; 2018 Oct; 10(1):132. PubMed ID: 30373654
[TBL] [Abstract][Full Text] [Related]
24. A Panel of Biomarkers for Diagnosis of Prostate Cancer Using Urine Samples.
Guo J; Yang J; Zhang X; Feng X; Zhang H; Chen L; Johnson H; Persson JL; Xiao K
Anticancer Res; 2018 Mar; 38(3):1471-1477. PubMed ID: 29491074
[TBL] [Abstract][Full Text] [Related]
25. [[-2] proPSA: A Novel Marker of Prostate Cancer].
Ishikura K
Rinsho Byori; 2015 Jan; 63(1):84-93. PubMed ID: 26524883
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen and other serum and urine markers in prostate cancer.
Stephan C; Ralla B; Jung K
Biochim Biophys Acta; 2014 Aug; 1846(1):99-112. PubMed ID: 24727384
[TBL] [Abstract][Full Text] [Related]
27. Beyond PSA: The Role of Prostate Health Index (phi).
Ferro M; De Cobelli O; Lucarelli G; Porreca A; Busetto GM; Cantiello F; Damiano R; Autorino R; Musi G; Vartolomei MD; Muto M; Terracciano D
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32053990
[TBL] [Abstract][Full Text] [Related]
28. Current biomarkers for diagnosing of prostate cancer.
Stephan C; Jung K; Ralla B
Future Oncol; 2015; 11(20):2743-55. PubMed ID: 26358139
[TBL] [Abstract][Full Text] [Related]
29. Current state of biomarkers for the diagnosis and assessment of treatment efficacy of prostate cancer.
Liu J; Li Y; Yang D; Yang C; Mao L
Discov Med; 2019 Jun; 27(150):235-243. PubMed ID: 31421692
[TBL] [Abstract][Full Text] [Related]
30. [New biomarkers in serum and urine for detection of prostate cancer].
Stephan C; Jung K; Miller K; Ralla B
Aktuelle Urol; 2015 Mar; 46(2):129-43. PubMed ID: 25897535
[TBL] [Abstract][Full Text] [Related]
31. Emerging biomarkers in the detection and prognosis of prostate cancer.
Filella X; Foj L
Clin Chem Lab Med; 2015 Jun; 53(7):963-73. PubMed ID: 25581761
[TBL] [Abstract][Full Text] [Related]
32. PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer.
Tosoian J; Loeb S
ScientificWorldJournal; 2010 Oct; 10():1919-31. PubMed ID: 20890581
[TBL] [Abstract][Full Text] [Related]
33. miRNAs as biomarkers in prostate cancer.
Casanova-Salas I; Rubio-Briones J; Fernández-Serra A; López-Guerrero JA
Clin Transl Oncol; 2012 Nov; 14(11):803-11. PubMed ID: 22855165
[TBL] [Abstract][Full Text] [Related]
34. Affinity Captured Urinary Extracellular Vesicles Provide mRNA and miRNA Biomarkers for Improved Accuracy of Prostate Cancer Detection: A Pilot Study.
Davey M; Benzina S; Savoie M; Breault G; Ghosh A; Ouellette RJ
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33172003
[TBL] [Abstract][Full Text] [Related]
35. Serum ProGRP as a novel biomarker of bone metastasis in prostate cancer.
Yu M; Yang C; Wang S; Zeng Y; Chen Z; Feng N; Ning C; Wang L; Xue L; Zhang Z
Clin Chim Acta; 2020 Nov; 510():437-441. PubMed ID: 32791134
[TBL] [Abstract][Full Text] [Related]
36. New biomarkers for diagnosis and prognosis of localized prostate cancer.
Chistiakov DA; Myasoedova VA; Grechko AV; Melnichenko AA; Orekhov AN
Semin Cancer Biol; 2018 Oct; 52(Pt 1):9-16. PubMed ID: 29360504
[TBL] [Abstract][Full Text] [Related]
37. Combining PHI and miRNAs as Biomarkers in Prostate Cancer Diagnosis and Prognosis.
Ibrahim NH; Abdellateif MS; Thabet G; Kassem SH; El-Salam MA; El-Leithy AA; Selim MM
Clin Lab; 2019 Jul; 65(7):. PubMed ID: 31307177
[TBL] [Abstract][Full Text] [Related]
38. The potential of cell-free and exosomal microRNAs as biomarkers in liquid biopsy in patients with prostate cancer.
de Nóbrega M; Dos Reis MB; Pereira ÉR; de Souza MF; de Syllos Cólus IM
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2893-2910. PubMed ID: 35922694
[TBL] [Abstract][Full Text] [Related]
39. Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis.
Agnello L; Vidali M; Giglio RV; Gambino CM; Ciaccio AM; Lo Sasso B; Ciaccio M
Clin Chem Lab Med; 2022 Jul; 60(8):1261-1277. PubMed ID: 35567430
[TBL] [Abstract][Full Text] [Related]
40. Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer.
Cani AK; Hu K; Liu CJ; Siddiqui J; Zheng Y; Han S; Nallandhighal S; Hovelson DH; Xiao L; Pham T; Eyrich NW; Zheng H; Vince R; Tosoian JJ; Palapattu GS; Morgan TM; Wei JT; Udager AM; Chinnaiyan AM; Tomlins SA; Salami SS
Eur Urol Oncol; 2022 Aug; 5(4):430-439. PubMed ID: 33812851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]